Advanced Viral Research Corp.'s CEO, Dr. Shalom Z. Hirschman, Interviewed by WallStreetReporter.com.

YONKERS, N.Y.--(BW HealthWire)--Dec. 15, 1999--

Discusses New Data on the Impact of the Anti-Viral Substance R on

AIDS Cocktail Therapy;

Successfully Building Company on a Foundation of Science

Dr. Shalom Z. Hirschman, president and CEO of Advanced Viral Research Corp. (OTCBB: ADVR), is a featured interview on WallStreetReporter.com (http://www.wallstreetreporter.com) through Monday, December 22. Advanced Viral Research Corp. is a biopharmaceutical firm focused on the research and development of drugs known as peptide-nucleic acid immunomodulators which have been shown to have beneficial effects against viral diseases, such as AIDS and Human Papilloma Virus (HPV).

During the interview, Dr. Hirschman discusses the company's latest research findings with respect to its flagship drug, Substance R (Reticulose(TM)), a non-toxic peptide-nucleic acid being developed as a broad spectrum anti-viral drug. Under the leadership of Dr. Hirschman, company scientists are expanding the molecular science of Substance R in order to develop future therapeutics. New data indicate Substance R may significantly enhance the effectiveness of the current AIDS cocktail treatment. It may also have promising therapeutic effects against other viral infections, including HPV.

Michael Wachs, analyst with The Wall Street Reporter, comments during the interview that, "investors should take a close look at an opportunity to get in on the ground floor of a company with a potential breakthrough treatment for AIDS and other diseases."

Dr. Hirschman also offers insight into his reasons for joining Advanced Viral Research Corp. and the steps he has taken to build the company into a true biopharmaceutical concern, based on a foundation of sound scientific research and cutting-edge innovation.

Dr. Hirschman had a 40-year career in academic medicine before joining Advanced Viral Research Corp. He has held important leadership positions in renowned medical centers and research institutions. He also founded one of New York City's first and most active AIDS treatment and research centers.

Dr. Hirschman joined Advanced Viral Research Corp. as president and CEO at the end of 1996. He believes good science is the foundation for company growth. Earlier this year, Dr. Hirschman established the Advanced Viral Research Institute to enable senior scientists to pursue basic biomedical research in an academically-oriented environment. Current research focuses on peptide-nucleic acid therapies, including Substance R.

Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical firm committed to researching, developing and bringing to market new effective therapies for viral and other diseases which will lead to the alleviation of human suffering and diseases worldwide. Its flagship drug, Substance R (Reticulose(TM)), is a non-toxic immunomodulator that has been shown to have beneficial therapeutic effects against viral diseases such as AIDS.

NOTE TO EDITORS: Interviews are available upon request with Dr. Hirschman. A copy of the press release entitled, "New Data Indicate Substance R May Enhance AIDS Cocktail Therapy," issued by Advanced Viral Research Corp., can be obtained by calling Jill Miller or Mike Rosen at Bratskeir & Company at [phone].

NOTE: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Substance R (Reticulose(TM)) is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries.